Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan 27:13:840923.
doi: 10.3389/fimmu.2022.840923. eCollection 2022.

Genetic Changes Driving Immunosuppressive Microenvironments in Oral Premalignancy

Roberto Rangel  1 , Curtis R Pickering  1 , Andrew G Sikora  1 , Michael T Spiotto  2
Affiliations
Review

Genetic Changes Driving Immunosuppressive Microenvironments in Oral Premalignancy

Roberto Rangel et al. Front Immunol. .

Abstract

Oral premalignant lesions (OPLs) are the precursors to oral cavity cancers, and have variable rates of progression to invasive disease. As an intermediate state, OPLs have acquired a subset of the genomic alterations while arising in an oral inflammatory environment. These specific genomic changes may facilitate the transition to an immune microenvironment that permits malignant transformation. Here, we will discuss mechanisms by which OPLs develop an immunosuppressive microenvironment that facilitates progression to invasive cancer. We will describe how genomic alterations and immune microenvironmental changes co-evolve and cooperate to promote OSCC progression. Finally, we will describe how these immune microenvironmental changes provide specific and unique evolutionary vulnerabilities for targeted therapies. Therefore, understanding the genomic changes that drive immunosuppressive microenvironments may eventually translate into novel biomarker and/or therapeutic approaches to limit the progression of OPLs to potential lethal oral cancers.

Keywords: CDKN2A; NOTCH1; TP53; head and neck cancer; immunosuppression.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Schema for immune/inflammatory microenvironment evolution during OPL progression. OPL are often strongly infiltrated with CD8+ T cells. Early low grade dysplasias also demonstrate tumoricidal and/or M1 TAMs. As dysplastic lesions progress, increased immunosuppressive M2 TAM, Treg, MDSCs and immunosuppressive molecules including PD-1/PD-L1 and A2AR. Created with BioRender.com.
Figure 2
Figure 2
Current OPL progression model. Schematic diagram showing the relative timing of genomic events during OPL progression. The stages are labeled early, middle, and late because the data are not well associated with specific histology. LOH, loss of hetorozygosity; WGS, whole genome sequencing; SNV, single nucleotide variant; CNA, copy number alteration. Modified from Califano and Gerstung. Created with BioRender.com.
Figure 3
Figure 3
Mutational changes that potentially alter the tumor microenvironment. Schematic diagram showing the common mutational changes in OPL can impact the immune microenvironment. TP53 mutants can activate NF-kB or inhibit the STING pathway to alter cytokine expression, increase TAM recruitment, increate Treg recruitment. CDKN2A mutants has been associated with immunogenic cold tumors through currently unknown mechanisms. NOTCH1 mutants was associated with altered MMP expression and decreased TAM infiltrations. Created with BioRender.com.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Warnakulasuriya S, Kujan O, Aguirre-Urizar JM, Bagan JV, Gonzalez-Moles MA, Kerr AR, et al. . Oral Potentially Malignant Disorders: A Consensus Report From an International Seminar on Nomenclature and Classification, Convened by the WHO Collaborating Centre for Oral Cancer. Oral Dis (2021) 27:1862–80. doi: 10.1111/odi.13704 - DOI - PubMed
    1. Iocca O, Sollecito TP, Alawi F, Weinstein GS, Newman JG, De Virgilio A, et al. . Potentially Malignant Disorders of the Oral Cavity and Oral Dysplasia: A Systematic Review and Meta-Analysis of Malignant Transformation Rate by Subtype. Head Neck (2020) 42:539–55. doi: 10.1002/hed.26006 - DOI - PubMed
    1. Petti S. Pooled Estimate of World Leukoplakia Prevalence: A Systematic Review. Oral Oncol (2003) 39:770–80. doi: 10.1016/S1368-8375(03)00102-7 - DOI - PubMed
    1. Monteiro L, Mello FW, Warnakulasuriya S. Tissue Biomarkers for Predicting the Risk of Oral Cancer in Patients Diagnosed With Oral Leukoplakia: A Systematic Review. Oral Dis (2021) 27:1977–92. doi: 10.1111/odi.13747 - DOI - PubMed
    1. Califano J, Westra WH, Meininger G, Corio R, Koch WM, Sidransky D. Genetic Progression and Clonal Relationship of Recurrent Premalignant Head and Neck Lesions. Clin Cancer Res (2000) 6:347–52. - PubMed

Publication types

MeSH terms